Primary Peptides Inc is a clinical-stage targeted protein degradation platform technology company. We are developing novel peptide therapeutics using two platform technologies: 1) peptide array for identifying, targeting, and disrupting specific protein-protein interactions; 2) peptide-mediated protein knockdown technology that can compete with small molecule PROTAC technology in degrading proteins of interest and can replace antisense and siRNA technology platforms in many indications with greater specificity and greater temporal precision. We have signed 4 pharma partnerships so far. Our 1st lead compound has finished a phase 1 clinical trial in healthy volunteers. The 2nd and 3rd lead compounds are in IND-enabling studies.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
K13, stroke indication. completed a phase 1 trial in healthy volunteers
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):